Parker Investment Management LLC Sells 3,205 Shares of Eli Lilly and Company $LLY

Parker Investment Management LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 63.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,819 shares of the company’s stock after selling 3,205 shares during the quarter. Eli Lilly and Company comprises 0.2% of Parker Investment Management LLC’s portfolio, making the stock its 25th biggest holding. Parker Investment Management LLC’s holdings in Eli Lilly and Company were worth $1,418,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Cercano Management LLC boosted its stake in Eli Lilly and Company by 15,627.0% during the 2nd quarter. Cercano Management LLC now owns 173,783 shares of the company’s stock valued at $135,469,000 after purchasing an additional 172,678 shares during the period. Jensen Investment Management Inc. acquired a new position in shares of Eli Lilly and Company during the second quarter worth approximately $161,060,000. Intech Investment Management LLC boosted its position in shares of Eli Lilly and Company by 18.9% in the second quarter. Intech Investment Management LLC now owns 168,692 shares of the company’s stock valued at $131,500,000 after acquiring an additional 26,857 shares during the period. Sculati Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 16.4% in the second quarter. Sculati Wealth Management LLC now owns 2,131 shares of the company’s stock valued at $1,661,000 after acquiring an additional 300 shares during the period. Finally, Cetera Investment Advisers grew its stake in shares of Eli Lilly and Company by 3.1% in the second quarter. Cetera Investment Advisers now owns 253,839 shares of the company’s stock worth $197,876,000 after acquiring an additional 7,552 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on LLY. Leerink Partners upgraded shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and upped their target price for the company from $886.00 to $1,104.00 in a research note on Monday, November 10th. Guggenheim reaffirmed a “buy” rating and set a $948.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 16th. Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Leerink Partnrs raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday, November 10th. Finally, UBS Group lifted their price objective on Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,015.11.

Eli Lilly and Company Stock Up 0.2%

Shares of LLY opened at $1,024.67 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a 50-day moving average price of $826.89 and a two-hundred day moving average price of $780.14. The stock has a market cap of $968.70 billion, a price-to-earnings ratio of 66.97, a P/E/G ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,033.62.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.